References

Cancer metabolism: looking forward

10.1038/s41568-021-00378-6 · 2021 · External reference

The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism

10.1038/s41568-019-0216-7 · 2020 · External reference

Metabolic regulation of cell growth and proliferation

10.1038/s41580-019-0123-5 · 2019 · External reference

Metabolic reprogramming and cancer progression

10.1126/science.aaw5473 · 2020 · External reference

Understanding the Warburg effect: the metabolic requirements of cell proliferation

10.1126/science.1160809 · 2009 · External reference

Aerobic glycolysis: meeting the metabolic requirements of cell proliferation

10.1146/annurev-cellbio-092910-154237 · 2011 · External reference

Glucose feeds the TCA cycle via circulating lactate

10.1038/nature24057 · 2017 · External reference

MYC and tumor metabolism: chicken and egg

10.15252/embj.201796438 · 2017 · External reference

Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat

10.1038/s41392-020-00235-2 · 2020 · External reference

Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction

10.1073/pnas.0810199105 · 2008 · External reference

The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type

10.1016/j.cmet.2011.12.015 · 2012 · External reference

MYC as a target for cancer treatment

10.1016/j.ctrv.2021.102154 · 2021 · External reference

Therapeutic targeting of “undruggable” MYC

10.1016/j.ebiom.2021.103756 · 2022 · External reference

MYC on the path to cancer

10.1016/j.cell.2012.03.003 · 2012 · External reference

Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis

10.1158/0008-5472.can-13-2034 · 2014 · External reference

The MYC oncogene - the grand orchestrator of cancer growth and immune evasion

10.1038/s41571-021-00549-2 · 2022 · External reference

The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice

10.1038/318533a0 · 1985 · External reference

MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes

10.1038/s41388-022-02458-9 · 2022 · External reference

MYC, metabolism, and cancer

10.1158/2159-8290.cd-15-0507 · 2015 · External reference

Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc

10.1074/jbc.c000023200 · 2000 · External reference

Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays

10.1128/mcb.24.13.5923-5936.2004 · 2004 · External reference

Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer

10.1186/s40170-021-00270-9 · 2021 · External reference

MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer

10.1038/nature03043 · 2004 · External reference

Sequential adaptive changes in a c-Myc-driven model of hepatocellular carcinoma

10.1074/jbc.m117.782052 · 2017 · External reference

Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer

10.1158/0008-5472.can-10-3590 · 2011 · External reference

Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer

10.1016/j.cmet.2016.01.007 · 2016 · External reference

Myc-driven murine prostate cancer shares molecular features with human prostate tumors

10.1016/s1535-6108(03)00197-1 · 2003 · External reference

AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer

10.1158/0008-5472.can-14-1490 · 2014 · External reference

Obesogenic high-fat diet and MYC cooperate to promote lactate accumulation and tumor microenvironment remodeling in prostate cancer

10.1158/0008-5472.can-23-0519 · 2024 · External reference

High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program

10.1038/s41467-019-12298-z · 2019 · External reference

Metabolic vulnerabilities of prostate cancer: diagnostic and therapeutic opportunities

10.1101/cshperspect.a030569 · 2018 · External reference

Metabolic reprogramming in prostate cancer

10.1038/s41416-021-01435-5 · 2021 · External reference

Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer

10.1038/ncomms11971 · 2016 · External reference

In vivo reprogramming of cancer metabolism by MYC

10.3389/fcell.2017.00035 · 2017 · External reference

Lactate metabolism in human lung tumors

10.1016/j.cell.2017.09.019 · 2017 · External reference

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis

10.1172/jci75836 · 2015 · External reference

MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer

10.15252/embr.201643068 · 2017 · External reference

The MYC oncogene cooperates with sterol-regulated element-binding protein to regulate lipogenesis essential for neoplastic growth

10.1016/j.cmet.2019.07.012 · 2019 · External reference

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer

10.1038/nm.4055 · 2016 · External reference

Alteration of the lipid profile in lymphomas induced by MYC overexpression

10.1073/pnas.1409778111 · 2014 · External reference

Characterization of MYC-induced tumorigenesis by in situ lipid profiling

10.1021/ac400479j · 2013 · External reference

Myc expression drives aberrant lipid metabolism in lung cancer

10.1158/0008-5472.can-15-3403 · 2016 · External reference

A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer

10.1038/s41388-020-01553-z · 2021 · External reference

Targeting ELOVL6 to disrupt c-MYC driven lipid metabolism in pancreatic cancer enhances chemosensitivity

10.1038/s41467-025-56894-8 · 2025 · External reference

Disrupting the MYC-TFEB circuit impairs amino acid homeostasis and provokes metabolic anergy

10.1158/0008-5472.can-21-1168 · 2022 · External reference

MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion

10.1158/1078-0432.ccr-18-4140 · 2019 · External reference

Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer

10.1172/jci139929 · 2021 · External reference

Prostate-specific oncogene OTUD6A promotes prostatic tumorigenesis via deubiquitinating and stabilizing c-Myc

10.1038/s41418-022-00960-x · 2022 · External reference

Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes

10.1038/s41416-019-0464-z · 2019 · External reference

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

10.1038/nature07823 · 2009 · External reference

MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism

10.1073/pnas.1507228112 · 2015 · External reference

MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma

10.1016/j.jhep.2020.07.039 · 2021 · External reference

Tumour hypoxia in driving genomic instability and tumour evolution

10.1038/s41568-024-00781-9 · 2025 · External reference

Molecular crosstalk between MYC and HIF in cancer

10.3389/fcell.2020.590576 · 2020 · External reference

HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity

10.1016/j.ccr.2007.04.001 · 2007 · External reference

Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1

10.1128/mcb.00440-07 · 2007 · External reference

HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice

10.1038/s41467-020-17873-3 · 2020 · External reference

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

10.1016/j.ccr.2008.10.016 · 2008 · External reference

Breast cancer stem cells secrete MIF to mediate tumor metabolic reprogramming that drives immune evasion

10.1158/0008-5472.can-23-2390 · 2024 · External reference

MIF loss impairs Myc-induced lymphomagenesis

10.1038/sj.cdd.4401653 · 2005 · External reference

Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells

10.1038/s41556-018-0083-6 · 2018 · External reference

MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of proinflammatory macrophages

10.1158/0008-5472.can-22-0232 · 2023 · External reference

Lactate in the tumour microenvironment: from immune modulation to therapy

10.1016/j.ebiom.2021.103627 · 2021 · External reference

Functional polarization of tumour-associated macrophages by tumour-derived lactic acid

10.1038/nature13490 · 2014 · External reference

Immunoediting instructs tumor metabolic reprogramming to support immune evasion

10.1016/j.cmet.2022.12.003 · 2023 · External reference

Targeting MYC at the intersection between cancer metabolism and oncoimmunology

10.3389/fimmu.2024.1324045 · 2024 · External reference

Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5-24 million UK adults

10.1016/s0140-6736(14)60892-8 · 2014 · External reference

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

10.1016/s0140-6736(08)60269-x · 2008 · External reference

Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies

10.1136/bmj.g7607 · 2015 · External reference

Intestinal MYC modulates obesity-related metabolic dysfunction

10.1038/s42255-021-00421-8 · 2021 · External reference

Proinflammatory CXCL12-CXCR4/CXCR7 signaling axis drives Myc-induced prostate cancer in Obese mice

10.1158/0008-5472.can-17-0284 · 2017 · External reference

Acetate metabolism in physiology, cancer, and beyond

10.1016/j.tcb.2019.05.005 · 2019 · External reference

The metabolic fate of acetate in cancer

10.1038/nrc.2016.87 · 2016 · External reference

The fat side of prostate cancer

10.1016/j.bbalip.2013.03.010 · 2013 · External reference

Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc

10.1038/s42255-024-01037-4 · 2024 · External reference

Obesity and cancer, a case for insulin signaling

10.1038/cddis.2015.381 · 2015 · External reference

Rethinking the relationship between insulin and cancer

10.1016/j.tem.2020.05.004 · 2020 · External reference

Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes

10.1186/bcr3089 · 2012 · External reference

The insulin and IGF signaling pathway sustains breast cancer stem cells by IRS2/PI3K-mediated regulation of MYC

10.1016/j.celrep.2022.111759 · 2022 · External reference

MYC in cancer: from undruggable target to clinical trials

10.1038/s41573-025-01143-2 · 2025 · External reference

Myc-Driven glycolysis is a therapeutic target in glioblastoma

10.1158/1078-0432.ccr-15-2274 · 2016 · External reference

Pivotal role of fatty acid synthase in c-MYC driven hepatocarcinogenesis

10.3390/ijms21228467 · 2020 · External reference

Fatty acid synthase: an emerging target in cancer

10.3390/molecules25173935 · 2020 · External reference

Targeting lipid metabolism in metastatic prostate cancer

10.1177/17588359231152839 · 2023 · External reference

Identifying strategies to target the metabolic flexibility of tumours

10.1038/s42255-020-0195-8 · 2020 · External reference

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

10.1111/bcp.14289 · 2020 · External reference

MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to Aurora kinase inhibition

10.1016/j.ccell.2016.12.005 · 2017 · External reference

13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression

10.1016/j.cmet.2011.04.012 · 2011 · External reference

Cancer recurrence monitoring using hyperpolarized [1-13C]pyruvate metabolic imaging in murine breast cancer model

10.1016/j.mri.2017.07.014 · 2017 · External reference